Astria Therapeutics, Inc.

NasdaqGM:ATXS Stock Report

Market Cap: US$539.5m

Astria Therapeutics Management

Management criteria checks 2/4

Astria Therapeutics' CEO is Jill Milne, appointed in Jun 2008, has a tenure of 16.5 years. total yearly compensation is $2.96M, comprised of 20.4% salary and 79.6% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $41.87K. The average tenure of the management team and the board of directors is 4.5 years and 9.2 years respectively.

Key information

Jill Milne

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage20.4%
CEO tenure16.5yrs
CEO ownership0.008%
Management average tenure4.5yrs
Board average tenure9.2yrs

Recent management updates

Recent updates

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 27

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

CEO Compensation Analysis

How has Jill Milne's remuneration changed compared to Astria Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$93m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$602k

-US$73m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$2mUS$568k

-US$52m

Sep 30 2022n/an/a

-US$48m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$3mUS$536k

-US$219m

Sep 30 2021n/an/a

-US$219m

Jun 30 2021n/an/a

-US$222m

Mar 31 2021n/an/a

-US$199m

Dec 31 2020US$1mUS$520k

-US$37m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$1mUS$501k

-US$26m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$1mUS$476k

-US$26m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$633kUS$462k

-US$27m

Compensation vs Market: Jill's total compensation ($USD2.96M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Jill's compensation has increased whilst the company is unprofitable.

CEO

Jill Milne (56 yo)

16.5yrs

Tenure

US$2,955,504

Compensation

Ms. Jill C. Milne, PhD is a Co-founder of Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.), has been its Director, President and Chief Executive Officer since June 2008. She se...

Leadership Team

NamePositionTenureCompensationOwnership
Jill Milne
Co-Founder16.5yrsUS$2.96m0.0078%
$ 41.9k
Noah Clauser
CFO & Treasurer5yrsUS$1.35m0%
$ 0
Christopher Morabito
Chief Medical Officer2.4yrsUS$1.32m0%
$ 0
Benjamin Harshbarger
Chief Legal Officer4.5yrsUS$845.83k0%
$ 0
Keri McGrail
Chief Human Resources Officer3.7yrsno datano data
Andrea Matthews
Chief Business Officer7.3yrsno datano data
Andrew Komjathy
Chief Commercial Officer5.3yrsno datano data
John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operations1.4yrsno datano data
Rafif Dagher
Senior VP and Head of Discoveryless than a yearno datano data

4.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: ATXS's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jill Milne
Co-Founder16.5yrsUS$2.96m0.0078%
$ 41.9k
Michael Kishbauch
Independent Director8.7yrsUS$157.67k0%
$ 0
Edward Scolnick
Member of Scientific Advisory Boardno datano datano data
Kenneth Bate
Independent Chairman of the Board10.9yrsUS$194.17kno data
Arthur Rubenstein
Member of Scientific Advisory Boardno datano datano data
Gregory Lapointe
Independent Director5.9yrsUS$163.67k0%
$ 0
Johannes Jacob Kastelein
Member of Scientific Advisory Boardno datano datano data
Michael Jirousek
Member of Scientific Advisory Board9.2yrsUS$589.63kno data
Jay Horton
Member of Scientific Advisory Boardno datano datano data
Roger Ulrich
Member of Scientific Advisory Boardno datano datano data
Eric Brass
Member of Scientific Advisory Boardno datano datano data
Sekar Kathiresan
Member of Scientific Advisory Boardno datano datano data

9.2yrs

Average Tenure

70yo

Average Age

Experienced Board: ATXS's board of directors are considered experienced (9.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:18
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Astria Therapeutics, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liisa BaykoEvercore ISI
Joseph PantginisH.C. Wainwright & Co.
Carol WertherH.C. Wainwright & Co.